← All trials
NCT00603330
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of LiegeLead sponsor
- Katholieke Universiteit LeuvenCollaborator
- CHU Mont-GodinneOverall official - principal investigator
- CHU Mont-GodinneCollaborator
- University of LiegeReponsible party - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- AZ VUB JetteOverall official - principal investigator
- ZNA AntwerpenOverall official - principal investigator
- AZ Sint-JanOverall official - principal investigator
- Maastricht UniversityOverall official - principal investigator
- Universitair Ziekenhuis GentOverall official - principal investigator
- Chu De LiègeStudy chair
- AZ Sint-JanCollaborator
- ZNA AntwerpenCollaborator
- Free University of BrusselsCollaborator
- University of AntwerpCollaborator
- Ghent UniversityCollaborator
- Jolimont Hospital Haine Saint PaulCollaborator
- Maastricht UniversityCollaborator
- University of LondonOverall official - principal investigator
- University of AntwerpOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.